Hepatitis C virus (HCV) infection poses significant adverse health effects. Improper use of vials, needles, syringes, intravenous bags, tubing, and connectors for injections and infusions is a current preventable cause of iatrogenic HCV transmission. Numerous cases have demonstrated the need for continued vigilance and the widespread nature of this iatrogenic infection risk across a variety of medical practice settings in the United States. Failure to implement the evidence-based Centers for Disease Control and Prevention (CDC) infection prevention guidelines exposes patients to preventable harm. The guidelines establish the requirement to notify patients in cases of suspected virus transmission, as well as to screen those patients who would not otherwise have been at risk for HCV seroconversion and other bloodborne pathogens. Legal and regulatory ramifications, including state, criminal, and tort laws, hold physicians and other health care professionals accountable to use safe injection practices. This article reviews the major health risks of HCV infection, significant effects of iatrogenic infection transmission, CDC guidelines for safe injection practices, and legal regulations and ramifications designed to promote safe injection practices.

Download full-text PDF

Source
http://dx.doi.org/10.7556/jaoa.2018.062DOI Listing

Publication Analysis

Top Keywords

safe injection
16
injection practices
16
hepatitis virus
8
virus transmission
8
hcv infection
8
iatrogenic infection
8
infection
5
iatrogenic
4
iatrogenic hepatitis
4
transmission
4

Similar Publications

The objective of this study was to evaluate the effect of injecting flue gas (CO, N, and O) originating from coal-fired power plants into a coal seam on CH extraction and CO geological storage. To this end, a multifield thermal-fluid-solid-coupled mathematical model of flue gas injection extraction was established. The results showed that with the increase in time increase, the volume concentration of CH decreased, but the CO, N, and O increased.

View Article and Find Full Text PDF

Efficacy and safety of PCSK9 inhibitors in real life.

Clin Investig Arterioscler

January 2025

Unidad de Lípidos y Riesgo Vascular, Servicio de Endocrinología y Nutrición, Hospital del Mar, Barcelona, España. Electronic address:

Objective: To confirm the effectiveness and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in daily clinical practice.

Methods: Retrospective observational study of patients from hospital registry of PCSK9 inhibitor treatment with a follow-up ≥ 6 months. The lipid-lowering effect and safety were evaluated.

View Article and Find Full Text PDF

Intratumoral delivery of Mitomycin C using bio-responsive Gellan Gum Nanogel: In-vitro evaluation and enhanced chemotherapeutic efficacy.

Int J Biol Macromol

January 2025

Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow 226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India. Electronic address:

Intratumoral drug delivery systems hold immense promise in overcoming the limitations of conventional IV chemotherapy, particularly in enhancing therapeutic efficacy and minimizing systemic side effects. In this study, we introduce a novel redox-responsive intratumoral nanogel system that combines the biocompatibility of natural polysaccharides with the tailored properties of synthetic polymers. The nanogel features a unique cross-linked architecture incorporating redox-sensitive segments, designed to leverage the elevated glutathione levels in the tumor microenvironment for controlled drug release.

View Article and Find Full Text PDF

The advent of once-weekly insulin icodec is a promising development in the care of individuals with diabetes. These once-weekly formulations aimed to improve patient adherence and quality of life for patients who find daily injection administration challenging. Insulin icodec has demonstrated comparable glycemic control to conventionally used daily basal insulins, such as insulin glargine and degludec, in the ONWARDS clinical trials.

View Article and Find Full Text PDF

Production of Hydrophobic Microparticles at Safe-To-Inject Sizes for Intravascular Administration.

Pharmaceutics

January 2025

Laboratory of Biointerface Chemistry, Department of Molecules and Materials, Faculty of Science and Technology, Technical Medical Centre and MESA+ Institute, University of Twente, 7522NB Enschede, The Netherlands.

Hydrophobic microparticles are one of the most versatile structures in drug delivery and tissue engineering. These constructs offer a protective environment for hydrophobic or water-sensitive compounds (e.g.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!